Madrigal Pharmaceuticals struck a series of deals with Suzhou Ribo Life Science and Ribocure Pharmaceuticals to license six preclinical siRNA programs aimed at metabolic dysfunction‑associated steatohepatitis (MASH), paying $60 million upfront and agreeing to as much as $4.4 billion in downstream milestones plus royalties. The transactions are part of Madrigal’s strategy to combine liver‑targeted gene‑silencing approaches with its marketed THR‑beta agonist Rezdiffra to create multi‑modality regimens for MASH. Madrigal described the acquisitions as pipeline acceleration after Rezdiffra’s market success and follows other recent deals, including a DGAT2 inhibitor from Pfizer. The company expects the siRNAs to enable genetically targeted combinations that could address complementary drivers of fatty‑liver disease.